Related references
Note: Only part of the references are listed.AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M. Weir et al.
CANCER RESEARCH (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications
Geraldine J. Liao et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M. Spoerke et al.
NATURE COMMUNICATIONS (2016)
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
Sean W Fanning et al.
eLife (2016)
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
Suzanne E. Wardell et al.
CLINICAL CANCER RESEARCH (2015)
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
Michel van Kruchten et al.
CANCER DISCOVERY (2015)
Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer
Brenda K. Edwards et al.
CANCER (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
Suzanne E. Wardell et al.
CLINICAL CANCER RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
Irene Kuter et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Hormonal therapy in breast cancer: A model disease for the personalization of cancer care
Shannon Puhalla et al.
MOLECULAR ONCOLOGY (2012)
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
Suzanne E. Wardell et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
Hannah M. Linden et al.
CLINICAL CANCER RESEARCH (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
Yoko S. DeRose et al.
NATURE MEDICINE (2011)
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)
S. Ohno et al.
ANNALS OF ONCOLOGY (2010)
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
Kathleen I. Pritchard et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer
Donald P. McDonnell et al.
CURRENT OPINION IN PHARMACOLOGY (2010)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
Henning Mouridsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome
Nicholas B. Berry et al.
MOLECULAR ENDOCRINOLOGY (2008)
NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Kendall W. Nettles et al.
NATURE CHEMICAL BIOLOGY (2008)
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
L. Perey et al.
ANNALS OF ONCOLOGY (2007)
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients
Lisa K. Dunnwald et al.
BREAST CANCER RESEARCH (2007)
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis
Davide Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
Hannah M. Linden et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
JS Lewis et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2005)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma - A prospectively planned combined survival analysis of two multicenter trials
A Howell et al.
CANCER (2005)
Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds
MA Iannone et al.
MOLECULAR ENDOCRINOLOGY (2004)
The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators
AL Wijayaratne et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)